Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester Academic Health Science Centre, Division of Evolution and Genomic Science, School of Biological Sciences, University of Manchester, Manchester, UK.
Medical Genomics Laboratory Department of Genetics, University of Alabama at Birmingham, Birmingham, AL, USA.
Genet Med. 2021 Sep;23(9):1779-1782. doi: 10.1038/s41436-021-01175-0. Epub 2021 Apr 20.
The LZTR1 gene has been associated with schwannomatosis tumor predisposition and is located in a region that is deleted in the great majority (89%) of patients with 22q11.2 deletion syndrome (22q11.2DS). Since it is known that approximately 1 in 500 people in the general population will develop a sporadic schwannoma and there are no reports of the occurrence of schwannoma in 22q11.2DS, we investigated whether whole-gene deletion of LZTR1 occurs in schwannomatosis and assessed the risk of schwannoma in 22q11.2DS.
We assessed the genetic testing results for LZTR1-associated schwannomatosis and the clinical phenotypes of patients with 22q11.2DS.
There were no reports of schwannoma in over 1,500 patients with 22q11.2DS. In addition, no patients meeting clinical diagnostic criteria for schwannomatosis had a whole-gene deletion in LZTR1. Only 1 patient in 110 with an apparently sporadic vestibular schwannoma had a constitutional whole-gene deletion of LZTR1.
People with a large 22q11.2 deletion may have a reduced risk of developing a schwannoma compared to the general population.
LZTR1 基因与神经鞘瘤病肿瘤易感性相关,位于 22q11.2 缺失综合征(22q11.2DS)患者中绝大多数(89%)缺失的区域。由于已知一般人群中约有 1/500 人会发生散发性神经鞘瘤,且 22q11.2DS 中没有神经鞘瘤发生的报道,我们研究了 LZTR1 基因是否会在神经鞘瘤病中发生全基因缺失,并评估了 22q11.2DS 中神经鞘瘤的风险。
我们评估了与 LZTR1 相关的神经鞘瘤病患者的基因检测结果和 22q11.2DS 患者的临床表型。
在超过 1500 例 22q11.2DS 患者中均无神经鞘瘤的报告。此外,没有符合神经鞘瘤病临床诊断标准的患者存在 LZTR1 的全基因缺失。在 110 例表现为散发性前庭神经鞘瘤的患者中,仅有 1 例存在 LZTR1 的结构全基因缺失。
与一般人群相比,携带大片段 22q11.2 缺失的人发生神经鞘瘤的风险可能降低。